We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

3 hedge funds and large institutions have $2.96M invested in Estrella Immunopharma in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 0 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

19.25% less ownership

Funds ownership: 32.4% → 13.16% (-19%)

64% less capital invested

Capital invested by funds: $8.18M → $2.96M (-$5.22M)

67% less funds holding

Funds holding: 9 → 3 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
3
Holders Change
-6
Holders Change %
-66.67%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$207K
2
MCP
Maso Capital Partners
Hong Kong
+$101K

Top Sellers

Rank Fund Capital Flow
1
HHGC
Hunting Hill Global Capital
New York
-$3.14M
2
SIA
SkyView Investment Advisors
New Jersey
-$1.35M
3
CS
Clear Street
New York
-$322K
4
SOA
Sea Otter Advisors
Florida
-$152K
5
MC
Meteora Capital
Florida
-$151K

ESLA Hedge Fund Activity: Q3 2023 in Review

3 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2023, worth a combined $2.96M — down 64% from $8.18M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ESLA and 2 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Jane Street, opening a new position worth an estimated $207K. The largest seller was Hunting Hill Global Capital, exiting entirely with an estimated $3.14M sold.

  • 3 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2023, down from 9 in Q2 2023.
  • Funds reported $2.96M of Estrella Immunopharma stock for Q3 2023, down 64% quarter-over-quarter.
  • 2 funds opened new Estrella Immunopharma positions in Q3 2023 and 8 closed out, a net change of -6 holders.
  • The largest Estrella Immunopharma buyer in Q3 2023 was Jane Street, an estimated $207K added.
  • The largest Estrella Immunopharma seller in Q3 2023 was Hunting Hill Global Capital, an estimated $3.14M sold.

Based on aggregated 13F filings for Q3 2023.